The US Food and Drug Administration has granted its stamp of approval to Thermo Fisher Scientific’s Oncomine Dx Target for use in helping to identify patients who might benefit from treatment with Eli Lilly and Company drug Retevmo (selpercatinib).
The test identifies patients who have RET-fusion positive locally advanced or metastatic non-small cell lung cancer (NSCLC), RET-fusion positive advanced or metastatic thyroid cancer and RET-mutation positive advanced or metastatic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?